Annovis Bio Files 8-K
Ticker: ANVS · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
Annovis Bio filed a standard 8-K, no major news.
AI Summary
Annovis Bio, Inc. filed an 8-K on August 6, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Annovis Bio, Inc. to the SEC, without disclosing new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any new material events or risks.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- QR Pharma, Inc. (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for Annovis Bio, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as of August 6, 2024.
What is Annovis Bio, Inc.'s principal executive office address?
Annovis Bio, Inc.'s principal executive office is located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What is Annovis Bio, Inc.'s telephone number?
Annovis Bio, Inc.'s telephone number is (484) 875-3192.
When was Annovis Bio, Inc. incorporated?
Annovis Bio, Inc. was incorporated in Delaware.
What was Annovis Bio, Inc.'s former company name?
Annovis Bio, Inc.'s former company name was QR Pharma, Inc., with a date of name change on December 2, 2009.
Filing Stats: 450 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-08-06 08:09:07
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2420928d1_8k.htm (8-K) — 26KB
- tm2420928d1_ex99-1.htm (EX-99.1) — 12KB
- tm2420928d1_ex99-1img001.jpg (GRAPHIC) — 42KB
- tm2420928d1_ex99-1img002.jpg (GRAPHIC) — 17KB
- 0001104659-24-086114.txt ( ) — 294KB
- anvs-20240806.xsd (EX-101.SCH) — 3KB
- anvs-20240806_lab.xml (EX-101.LAB) — 33KB
- anvs-20240806_pre.xml (EX-101.PRE) — 22KB
- tm2420928d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On August 6, 2024, Annovis Bio, Inc. ("The Company") issued a press release announcing preclinical data with respect to its lead compound, Buntanetap, when combined with a glucagon-like peptide 1 ("GLP-1") agonist in a mouse model of Alzheimer's disease. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. The following exhibits are being furnished herewith: (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated August 6, 2024 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: August 6, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer